The Bayer Corporation
announced that it has teamed
up with Us Too! International to offer Continuous Care, a program for advanced
prostate cancer patients using the leuprolide acetate implant (Viadur). The
program provides appointment reminders, education, support materials, and
valuable health coupons.
"Us Too! encourages voluntary programs (such as Bayer’s
Continuous Care program) that seek to disseminate information and provide
ongoing support to those affected by prostate cancer," said John A. Page,
fhimss, president and CEO, Us Too!. "We appreciate the opportunity to work
with a company so dedicated to men’s health, and look forward to continuing
our commitment to meeting the needs of prostate cancer patients and their
"Because the annual implantation of Viadur is just one
aspect of a comprehensive approach to patient management, Continuous Care offers
patients year-long support and education and helps them stay on track with their
treatment program," said Nancy Bryan, vice president, Bayer Men’s Health.
"And with the help of Us Too!, we will further enhance patient support,
thereby strengthening our commitment to help those with advanced prostate
The implant delivers a continuous 12-month infusion of
leuprolide, which is a luteinizing hormone-releasing hormone (LHRH) agonist, to
patients with advanced prostate cancer. More information about the implant and
its mechanism of action can be found at http://viadur.com.
The most common systemic side effects associated with the use of the
leuprolide implant include hot flashes (67.9%), asthenia (7.6%), gynecomastia
(6.9%), depression (5.3%), and sweating (5.3%). The most common local side
effects are bruising (34.6%) and burning (5.6%).